46 research outputs found

    Random line tessellations of the plane: statistical properties of many-sided cells

    Full text link
    We consider a family of random line tessellations of the Euclidean plane introduced in a much more formal context by Hug and Schneider [Geom. Funct. Anal. 17, 156 (2007)] and described by a parameter \alpha\geq 1. For \alpha=1 the zero-cell (that is, the cell containing the origin) coincides with the Crofton cell of a Poisson line tessellation, and for \alpha=2 it coincides with the typical Poisson-Voronoi cell. Let p_n(\alpha) be the probability for the zero-cell to have n sides. By the methods of statistical mechanics we construct the asymptotic expansion of \log p_n(\alpha) up to terms that vanish as n\to\infty. In the large-n limit the cell is shown to become circular. The circle is centered at the origin when \alpha>1, but gets delocalized for the Crofton cell, \alpha=1, which is a singular point of the parameter range. The large-n expansion of \log p_n(1) is therefore different from that of the general case and we show how to carry it out. As a corollary we obtain the analogous expansion for the {\it typical} n-sided cell of a Poisson line tessellation.Comment: 26 pages, 3 figure

    Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso.

    No full text
    In an urban district hospital in Burkina Faso we investigated the relative proportions of HIV-1, HIV-2 and HIV-1/2 among those tested, the baseline sociodemographic and clinical characteristics, and the response to and outcome of antiretroviral therapy (ART). A total of 7368 individuals (male=32%; median age=34 years) were included in the analysis over a 6 year period (2002-2008). The proportions of HIV-1, HIV-2 and dual infection were 94%, 2.5% and 3.6%, respectively. HIV-1-infected individuals were younger, whereas HIV-2-infected individuals were more likely to be male, have higher CD4 counts and be asymptomatic on presentation. ART was started in 4255 adult patients who were followed up for a total of 8679 person-years, during which time 469 deaths occurred. Mortality differences by serotype were not statistically significant, but were generally worse for HIV-2 and HIV-1/2 after controlling for age, CD4 count and WHO stage. Among severely immune-deficient patients, mortality was higher for HIV-2 than HIV-1. CD4 count recovery was poorest for HIV-2. HIV-2 and dually infected patients appeared to do less well on ART than HIV-1 patients. Reasons may include differences in age at baseline, lower intrinsic immune recovery in HIV-2, use of ineffective ART regimens (inappropriate prescribing) by clinicians, and poor drug adherence
    corecore